[Erlotinib. A new option for non-small cell lung cancer].
Polk
Bettina
B
Redaktion Medizinische Monatsschrift für Pharmazeuten, Birkenwaldstr. 44, 70191 Stuttgart. bpolk@wissenschaftlicheverlagsgesellschaft.de
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride